Sökning: "Henrik Green"
Visar resultat 1 - 5 av 15 avhandlingar innehållade orden Henrik Green.
1. Pharmacogenetic Studies of Paclitaxel in Ovarian Cancer : focus on interindividual differences in pharmacodynamics and pharmacokinetics
Sammanfattning : Ovarian cancer is one of the most common female cancer diseases in the world today and in Sweden more than 800 new cases are diagnosed every year. The standard treatment consists of chemotherapy with paclitaxel in combination with carboplatin after initial cytoreductive surgery. LÄS MER
2. Designing and Evaluating Human-Robot Communication : Informing Design through Analysis of User Interaction
Sammanfattning : This thesis explores the design and evaluation of human-robot communication for service robots that use natural language to interact with people. The research is centred around three themes: design of human-robot communication; evaluation of miscommunication in human-robot communication; and the analysis of spatial influence as empiric phenomenon and design element. LÄS MER
3. Pharmacogenetic biomarkers for chemotherapy-induced adverse drug reactions
Sammanfattning : Cancer is a serious disease expected to be the world-leading cause of death in the 21st century. The use of harsh chemotherapies is motivated and accepted but, unfortunately, is often accompanied by severe toxicity and adverse drug reactions (ADRs). LÄS MER
4. Taxane-Induced Peripheral Neuropathy among Early-Stage Breast Cancer Survivors : Prevalence, Risk Factors, Quality of Life and Genetic Prediction Models
Sammanfattning : Background: Taxane-induced peripheral neuropathy (TIPN) is a common and distressful side effect. Little is known on how long TIPN persist and its effect on health-related quality of life (HRQL). LÄS MER
5. Prognostic markers in acute myeloid leukemia : A candidate gene approach
Sammanfattning : The standard treatment of acute myeloid leukemia (AML) consists of induction chemotherapy, most commonly daunorubicin together with the nucleoside analogue cytarabine (Ara-C), followed by consolidation chemotherapy and in selected cases allogenic stem cell transplantation (allo-SCT). Despite a high initial response rate, a considerable proportion of all AML cases eventually suffer from relapse and the five-year overall survival rate in patients >60 years is only around 15%. LÄS MER